KRAS and non-small cell lung carcinoma: Recently, the discovery of a cryptic allosteric pocket (switch II [SII] pocket) in K-Ras4B has challenged this paradigm and enabled the rapid development of therapeutics to target K-Ras(G12C) mutant cancers,12,13 including the FDA-approved drugs LUMAKRAS (sotorasib)14 and Krazati (adagrasib)15 for the treatment of non-small cell lung cancer.